Current Report Filing (8-k)
May 05 2023 - 5:16PM
Edgar (US Regulatory)
false
0001625101
0001625101
2023-05-04
2023-05-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 4, 2023
Pulse Biosciences, Inc.
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
Delaware
|
001-37744
|
46-5696597
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
3957 Point Eden Way |
Hayward, California 94545
|
(Address of Principal Executive Offices) (Zip Code)
|
510-906-4600 |
(Registrant’s Telephone Number, Including Area Code) |
Not Applicable
|
(Former Name or Former Address, If Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
Common stock, $0.001 par value per share
|
PLSE
|
The Nasdaq Stock Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
The board of directors of Pulse Biosciences, Inc. (the “Company”) has approved certain changes to the compensation payable to the Company’s Chief Executive Officer, Kevin Danahy, and to its Chief Technology Officer, Darrin Uecker. Pursuant to amendments dated May 4, 2023 and May 5, 2023, respectively, Messrs. Danahy and Uecker will each receive base salary compensation of $450,000 per year, less applicable withholdings, and new cash bonus targets of 88.88%. Previously, both executive officers had salaries equal to $400,000 per year and 100% bonus targets.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
PULSE BIOSCIENCES, INC.
|
|
|
|
|
|
|
|
Date: May 5, 2023
|
By:
|
/s/ Kevin P. Danahy
|
|
|
|
Kevin P. Danahy
|
|
|
|
Chief Executive Officer
|
|
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2023 to Aug 2024